Register      Login
Journal of Primary Health Care Journal of Primary Health Care Society
Journal of The Royal New Zealand College of General Practitioners
Shopping Cart: ( empty )
You are here: Home > Journals > HC > HC21122
RESEARCH ARTICLE (Open Access)
Contents Vol 14(1)

Decision-making on listing new medicines for public funding in New Zealand: the case of ‘new’ type 2 diabetes medications

Farzana Sarkisova https://orcid.org/0000-0003-3681-9205 1 , Charon Lessing https://orcid.org/0000-0002-3841-0334 1 * , Caroline Stretton https://orcid.org/0000-0002-9141-7180 1
+ Author Affiliations
- Author Affiliations

1 School of Public Health and Interdisciplinary Studies, Auckland University of Technology, 90 Akoranga Drive, Northcote 0627, Auckland, New Zealand.

* Correspondence to: charon.lessing@aut.ac.nz

Journal of Primary Health Care 14(1) 13-20 https://doi.org/10.1071/HC21122
Published: 13 April 2022

© 2022 The Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of The Royal New Zealand College of General Practitioners. This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND)

Abstract

Introduction: New medicines for the management of type 2 diabetes became available internationally in 2005, yet only in 2018 did the first of these become available in New Zealand. Access to these new medicines in New Zealand is largely dependent on decisions made by the Pharmaceutical Management Agency (PHARMAC).

Aim: This study sought to describe the decision-making processes to better understand access to new medicines in New Zealand.

Methods: We conducted an analysis of publicly accessible information on therapeutic committee deliberations, prices of medicines and registration and formulary listing dates.

Results: Prices for the new diabetes medicines in New Zealand are lower than comparator countries, but access to them takes longer.

Discussion: Given that knowledge on efficacy, safety and quality is widely available to support decision-making on new medicines, differences in access to them between nations appears to depend on the fourth hurdle of cost. However, we suggest that a rush to market is the norm, that activities of the pharmaceutical industry and regulatory agencies are less transparent than desirable, and that greater focus on availability of safety data is required. Deliberations of PHARMAC therapeutic committees are robust yet protracted. Opportunities to expedite decision-making, as well as resolving inequities, may be worthy of examination.

Keywords: access to medicines, diabetes, drug costs, healthcare funding, HTA, PHARMAC, pharmaceuticals, therapeutics committee.


References

[1]  New Zealand Ministry of Health. New Zealand health survey annual data explorer. Indicator: type 2 diabetes (diagnosed when aged 25 years or older used as a proxy for type 2 diabetes). 2020. Available at https://minhealthnz.shinyapps.io/nz‐health‐survey‐2020‐21‐annual‐data‐explorer/_w_7b1c4f48/#!/ [cited 8 September 2021]

[2]  PricewaterhouseCoopers New Zealand. The economic and social cost of type 2 diabetes. 2021. Available at https://healthierlives.co.nz/wp-content/uploads/Economic-and-Social-Cost-of-Type-2-Diabetes-FINAL-REPORT.pdf [cited 5 July 2021]

[3]  Krebs J, Coppell K, Cresswell P, et al. Access to diabetes drugs in New Zealand is inadequate. NZ Med J 2016; 129 6–9.

[4]  Rawlins MD. Crossing the fourth hurdle. Br J Clin Pharmacol 2012; 73 855–860.
| Crossing the fourth hurdle.Crossref | GoogleScholarGoogle Scholar | 22404227PubMed |

[5]  New Zealand Medicines and Medical Devices Safety Authority. About Medsafe. 2020. Available at https://www.medsafe.govt.nz/other/about.asp#pre [cited 8 September 2020]

[6]  New Zealand Pharmaceutical Management Agency. Operating Policies and Procedures Manual 4th edn. 2020. Available at https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/policies-manuals-and-processes/operating-policies-and-procedures/ [cited 8 September 2021]

[7]  New Zealand Pharmaceutical Management Agency. Supporting information about the Factors for Consideration. 2020. Available at https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/policies-manuals-and-processes/factors-for-consideration/supporting-information-for-the-factors-for-consideration/ [cited 8 September 2021]

[8]  New Zealand Pharmaceutical Management Agency. Pharmacology and Therapeutics Advisory Committee (PTAC). 2021. Available at https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ [cited 3 September 2021]

[9]  New Zealand Pharmaceutical Management Agency. Online Pharmaceutical Schedule. 2021. Available at https://www.pharmac.govt.nz/wwwtrs/ScheduleOnline.php [cited 8 September 2021]

[10]  New Zealand Pharmaceutical Management Agency. Special Authority applications. 2021. Available at https://pharmac.govt.nz/medicine-funding-and-supply/make-an-application/special-authority-forms/ [cited 8 September 2021]

[11]  Wonder M, Milne R. Access to new medicines in New Zealand compared to Australia. NZ Med J 2011; 124 12–28.

[12]  Taylor C, Wonder M. Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand. Aust Health Rev 2015; 39 455–461.
| Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.Crossref | GoogleScholarGoogle Scholar | 25751688PubMed |

[13]  Wonder M, Fisher R. Subsidised access to new melanoma drugs: in need of further innovation? NZ Med J 2016; 129 37–54.

[14]  Rawson NS. Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand. Regul Toxicol Pharmacol 2019; 101 24–28.
| Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand.Crossref | GoogleScholarGoogle Scholar | 30391284PubMed |

[15]  New Zealand Pharmaceutical Management Agency. Approval of multi-product funding agreement with Novartis. 2018. Available at https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/approval-of-multi-product-funding-agreement-with-novartis/ [cited 8 September 2021]

[16]  New Zealand Pharmaceutical Management Agency. Decision to fund two new medicines for type 2 diabetes – Amended with Q&A. 2021. Available at https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-fund-two-new-medicines-for-type-2-diabetes/ [cited 9 September 2021]

[17]  New Zealand Society for the Study of Diabetes. Special report: NZSSD type 2 diabetes management guidelines 2021. 2021. Available at https://www.researchreview.co.nz/nz/clinical-area/general-medicine/general-practice/special-report-nzssd-type-2-diabetes-management-g.aspx?hash=d171e98ec4f85f61af1a7e99b0cc2ef826a2f65101e5d8b8ab22216de258abeb [cited 8 September 2021]

[18]  New Zealand Pharmaceutical Management Agency. Uptake of medicines for type 2 diabetes. 2021. Available at https://pharmac.govt.nz/news-and-resources/uptake-of-medicines-for-type-2-diabetes/ [cited 8 September 2021]

[19]  New Zealand Medicines and Medical Devices Safety Authority. Product/Application Search. 2021. Available at https://www.medsafe.govt.nz/regulatory/DbSearch.asp [cited 8 September 2021]

[20]  Australian Government Department of Health: Pharmaceutical Benefits Scheme. Public summary documents by product. 2021. Available at https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/public-summary-documents-by-product [cited 6 September 2021]

[21]  Organisation for Economic Co-operation and Development. Exchange rates. 2021. Available at https://data.oecd.org/conversion/exchange-rates.htm [cited 8 September 2021]

[22]  Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41 2669–2701.
| Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Crossref | GoogleScholarGoogle Scholar | 30291106PubMed |

[23]  American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021; 44 S111–S124.
| American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021.Crossref | GoogleScholarGoogle Scholar | 33298420PubMed |

[24]  New Zealand Formulary. Diabetes mellitus. 2021. Available at https://nzf.org.nz/nzf_3624?searchterm=Diabetes [cited 20 December 2021]

[25]  National Institute for Health and Care Excellence. NICE guideline: Type 2 diabetes in adults: management. 2021. Available at https://www.nice.org.uk/guidance/ng28 [cited 12 December 2021]

[26]  Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020 43 487–493.
| 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Crossref | GoogleScholarGoogle Scholar |

[27]  New Zealand Ministry of Health. Type 2 Diabetes Management Guidance. 2021. Available at https://t2dm.nzssd.org.nz/ [cited 8 September 2021]

[28]  United States Food and Drug Administration. Drug Approval Package: Exenatide. 2005. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_ByettaTOC.cfm [cited 8 September 2021]

[29]  New Zealand Medicines and Medical Devices Safety Authority. New Zealand data sheet: Byetta. 2021. Available at https://www.medsafe.govt.nz/profs/Datasheet/b/Byettainj.pdf [cited 12 December 2021]

[30]  Pharmacology and Therapeutics Advisory Committee. PTAC meeting–8 & 9 August 2007. 2007. Available at https://www.pharmac.govt.nz/assets/ptac-minutes-2007-08.pdf [cited 12 December 2021]

[31]  National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update): NICE Clinical Guidelines, No. 66. London: Royal College of Physicians; 2008. Available at https://www.ncbi.nlm.nih.gov/books/NBK53885/

[32]  Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35 1364–1379.
| Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Crossref | GoogleScholarGoogle Scholar | 22517736PubMed |

[33]  New Zealand Pharmaceutical Management Agency. Specialist advisory committees. 2021. Available at https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/ [cited 12 December 2021]

[34]  New Zealand Pharmaceutical Management Agency. Request for information on anti-diabetic agents. 2015. Available at https://www.pharmac.govt.nz/assets/rfi-2015-02-12-anti-diabetic-agents.pdf [cited 12 December 2021]

[35]  New Zealand Pharmaceutical Management Agency. Request for proposals – supply of diabetes agents: SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors. 2020. Available at https://www.pharmac.govt.nz/assets/rfp-2010-01-15-diabetes-agents.pdf [cited 12 December 2021]

[36]  Australian Government Department of Health: Pharmaceutical Benefits Scheme. PBS Publications Archive: Schedule of Pharmaceutical Benefits. Effective 1 August 2010. 2010. Available at https://www.pbs.gov.au/publication/schedule/2010/2010-08-01-general-schedule.pdf [cited 22 November 2021]

[37]  Australian Government Department of Health: Pharmaceutical Benefits Scheme. PBS Publications Archive: Schedule of Pharmaceutical Benefits. Effective 1 June 2018. 2018. Available at https://www.pbs.gov.au/publication/schedule/2018/06/2018-06-01-general-schedule.pdf [cited 9 September 2021]

[38]  New Zealand Medicines and Medical Devices Safety Authority. New Zealand data sheet: Galvus tablet. 2020. Available at https://www.medsafe.govt.nz/profs/Datasheet/g/galvustab.pdf [cited 12 December 2021]

[39]  Australian Government Department of Health: Pharmaceutical Benefits Scheme. PBS Publications Archive: Schedule of Pharmaceutical Benefits. Effective 1 August 2008. 2008. Available at https://www.pbs.gov.au/publication/schedule/2008/2008-08-01-general-schedule.pdf [cited 22 November 2021]

[40]  United States Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. Available at https://www.accessdata.fda.gov/scripts/cder/daf/ [cited 8 December 2021]

[41]  European Medicines Agency. Search medicines on the EMA website. 2021. Available at https://www.ema.europa.eu/en/medicines [cited 8 December 2021]

[42]  New Zealand Medicines and Medical Devices Safety Authority. Data sheets and consumer medicine information. 2020. Available at https://www.medsafe.govt.nz/Medicines/infoSearch.asp [cited 8 December 2021]

[43]  New Zealand Pharmaceutical Management Agency. Application Tracker. Available at https://connect.pharmac.govt.nz/apptracker/s/ [cited 8 September 2021]

[44]  Australian Government Department of Health: Pharmaceutical Benefits Scheme. PBS Publications Archive: Schedule of Pharmaceutical Benefits. 2021. Available at https://www.pbs.gov.au/info/publication/schedule/archive [cited 8 December 2021]

[45]  Diabetes Subcommittee of the Pharmacology and Therapeutics Advisory Committee. Diabetes Subcommittee of PTAC: Meeting held 21 August 2009. 2009. Available at https://www.pharmac.govt.nz/assets/ptac-diabetes-subcommittee-minutes-2009-08.pdf [cited 8 September 2021]

[46]  Pharmacology and Therapeutics Advisory Committee. PTAC meeting held 12 & 13 November 2009. 2009. Available at https://www.pharmac.govt.nz/assets/ptac-minutes-2009-11.pdf [cited 8 September 2021]

[47]  Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;
| Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.Crossref | GoogleScholarGoogle Scholar | 18646086PubMed |

[48]  Terhune C, Respaut R. J&J kept quiet on popular diabetes drug as red flags multiplied. Medscape. 2021. Available at https://www.medscape.com/viewarticle/964393?spon=34&uac=70499HJ&impID=3874272&sso=true&faf=1&src=WNL_mdpls_211214_mscpedit_fmed

[49]  Australian Government Department of Health: Pharmaceutical Benefits Scheme. PBS Publications Archive: Schedule of Pharmaceutical Benefits. Effective 1 December 2013. 2013. Available at https://www.pbs.gov.au/publication/schedule/2013/12/2013-12-01-general-schedule.pdf [cited 22 November 2021]

[50]  United States Food and Drug Administration. Drug Approval Package: Invokana. 2013. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000TOC.cfm [cited 16 December 2021]

[51]  New Zealand Medicines and Medical Devices Safety Authority. New Zealand data sheet: Jardiance. 2019. Available at https://www.medsafe.govt.nz/profs/Datasheet/j/jardiancetab.pdf [cited 16 December 2021]

[52]  United States Food and Drug Administration. Potential signals of serious risks/new safety information identified by the FDA Adverse Event Reporting System (Faers). 2020. Available at https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/october-december-2020-potential-signals-serious-risksnew-safety-information-identified-fda-adverse [cited 16 December 2021]

[53]  United States Food and Drug Administration. FDA Drug Safety Podcast: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). 2017. Available at https://www.fda.gov/drugs/fda‐drug‐safety‐podcasts/fda‐drug‐safety‐podcast‐fda‐confirms‐increased‐risk‐leg‐and‐foot‐amputations‐diabetes‐medicine [cited 19 December 2021]

[54]  United States Food and Drug Administration. FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. 2015. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet [cited 19 December 2021]

[55]  International Business Machines Corporation. IBM Micromedex Red Book. 2021. Available at https://www.ibm.com/products/micromedex-red-book [cited 20 December 2021]

[56]  BMJ group. British National Formulary. 2021. Available at https://www.bnf.org/products/bnf-online/ [cited 17 February 2020]

[57]  National Health Service. Electronic Drug Tariff. 2020. Available at http://www.drugtariff.nhsbsa.nhs.uk [cited 17 February 2020]

[58]  Pharmacy Retailing (NZ) Ltd. ProPharma. 2020. Available at https://www.propharma.co.nz/Login.aspx [cited 14 February 2020]

[59]  Daemmrich A, Krücken G. Risk versus risk: decision-making dilemmas of drug regulation in the United States and Germany. Sci Cult 2000; 9 505–534.
| Risk versus risk: decision-making dilemmas of drug regulation in the United States and Germany.Crossref | GoogleScholarGoogle Scholar |

[60]  Evans J, Laking G, Strother M, et al. Mind the gap: an analysis of foregone health gains from unfunded cancer medicines in New Zealand. Semin Oncol 2016; 43 625–637.
| Mind the gap: an analysis of foregone health gains from unfunded cancer medicines in New Zealand.Crossref | GoogleScholarGoogle Scholar | 28061980PubMed |

[61]  Vitry A, Shin NH, Vitre P. Assessment of the therapeutic value of new medicines marketed in Australia. J Pharm Policy Pract 2013; 6 2
| Assessment of the therapeutic value of new medicines marketed in Australia.Crossref | GoogleScholarGoogle Scholar | 24764537PubMed |

[62]  van Luijn JC, Gribnau FW, Leufkens HG. Superior efficacy of new medicines? Eur J Clin Pharmacol 2010; 66 445–448.
| Superior efficacy of new medicines?Crossref | GoogleScholarGoogle Scholar | 20224944PubMed |

[63]  Diabetes Subcommittee of the Pharmacology and Therapeutics Advisory Committee. Diabetes Subcommittee of PTAC: Meeting held 10 October 2016. 2016. Available at https://www.pharmac.govt.nz/assets/ptac-diabetes-subcommittee-minutes-2016-10.pdf [cited 8 September 2021]

[64]  Diabetes Subcommittee of the Pharmacology and Therapeutics Advisory Committee. Diabetes Subcommittee of PTAC: Meeting held 19 March 2019. 2019. Available at https://www.pharmac.govt.nz/assets/ptac-diabetes-subcommittee-minutes-2019-03.pdf [cited 8 September 2021]

[65]  New Zealand Pharmaceutical Management Agency. Media release: PHARMAC to fund new diabetes medicines with amended Special Authority criteria. 2020. Available at https://pharmac.govt.nz/news-and-resources/news/pharmac-to-fund-new-diabetes-medicines-with-amended-special-authority-criteria/ [cited 8 September 2021]

[66]  Yu D, Zhao Z, Osuagwu UL, et al. Ethnic differences in mortality and hospital admission rates between Māori, Pacific, and European New Zealanders with type 2 diabetes between 1994 and 2018: a retrospective, population-based, longitudinal cohort study. Lancet Glob Health 2021; 9 e209–e217.
| Ethnic differences in mortality and hospital admission rates between Māori, Pacific, and European New Zealanders with type 2 diabetes between 1994 and 2018: a retrospective, population-based, longitudinal cohort study.Crossref | GoogleScholarGoogle Scholar | 33069275PubMed |

[67]  New Zealand Ministry of Health. Mortality and demographic data 2006. 2019. Available at https://www.health.govt.nz/publication/mortality-and-demographic-data-2006 [cited 9 September 2021]

[68]  New Zealand Pharmaceutical Management Agency. Achieving medicine access equity in Aotearoa New Zealand: towards a theory of change. 2019. Available at https://pharmac.govt.nz/assets/achieving-medicine-access-equity-in-aotearoa-new-zealand-towards-a-theory-of-change.pdf [cited 8 September 2021]

[69]  New Zealand Pharmaceutical Management Agency. Proposal to fund two new medicines for type 2 diabetes. 2020. Available at https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-fund-two-new-medicines-for-type-2-diabetes/

[70]  New Zealand Pharmaceutical Management Agency. Te rautaki o te whaioranga. Māori responsiveness strategy. 2020. Available at https://pharmac.govt.nz/assets/Te-Whaioranga-August-2020.pdf [cited 8 September 2021]

[71]  New Zealand Pharmaceutical Management Agency. The consultation feedback on a proposal to fund two new treatments for type 2 diabetes and amend the contractual terms for one currently funded diabetes treatment through provisional agreements with three suppliers. 2020. Available at https://pharmac.govt.nz/assets/2020-diabetes-RFP-combined-consultation-responses-for-release-under-OIA.pdf [cited 8 September 2021]

[72]  New Zealand Pharmaceutical Management Agency. Decision to fund rosuvastatin for people with high cholesterol. 2021. Available at https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-08-17-decision-rosuvastatin/ [cited 8 September 2021]

[73]  Morgan SG, Leopold C, Wagner AK. Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverage. CMAJ 2017; 189 e794–e799.
| Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverage.Crossref | GoogleScholarGoogle Scholar | 28606975PubMed |

[74]  Cumming J, Mays N, Daubé J. How New Zealand has contained expenditure on drugs. Br Med J 2010; 340 1224–1227.
| How New Zealand has contained expenditure on drugs.Crossref | GoogleScholarGoogle Scholar |